Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11760587 | 0.94 | SMN1; SMN2 (0.60) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL224789 | 0.94 | MAPT (0.66) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL10987845 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL4423281 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL28105634 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL6208836 | 0.89 | SMN1; SMN2 (0.82) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL11036075 | 0.88 | SMN1; SMN2 (0.67) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL73828 | 0.87 | FFAR1 (0.65) | FFAR1MAOBGFERMAOAKEAP1 | |
| SCHEMBL69789 | 0.87 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| Hydrochloric Acid SCHEMBL10867576 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| EP-3274322-B1 | STABLE COMPOSITIONS FOR PREVENTION / PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS | THE UNIV OF MISSISSIPPI (US) | 2024-08-14 | — | — | EP | claimed |
| US-20240238317-A1 | METHODS FOR REDUCING INTRAOCULAR PRESSURE | UNIV MISSISSIPPI (US) | 2024-07-18 | — | — | US | claimed |
| CN-118103073-A | Method for reducing intraocular pressure | 密西西比大学 | 2024-05-28 | — | — | CN | claimed |
| CN-118056598-A | Preparation method of pervaporation membrane, application of pervaporation membrane in hydrogen chloride gas refining and refining method of pervaporation membrane | 万华化学集团股份有限公司 | 2024-05-21 | — | — | CN | claimed |
| EP-4337319-A1 | METHODS FOR REDUCING INTRAOCULAR PRESSURE | University of Mississippi (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4267118-A1 | XANTHOPHYLL DERIVATIVES | Axelyf ehf. (IS) | 2023-11-01 | — | — | EP | claimed |
| WO-2022241456-A1 | METHODS FOR REDUCING INTRAOCULAR PRESSURE | UNIVERSITY OF MISSISSIPPI (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022140580-A1 | XANTHOPHYLL DERIVATIVES | ALMARSSON ORN (US) | 2022-06-30 | — | — | WO | claimed |
| EP-3059004-B1 | METHOD FOR REMOVING SOX FROM GAS WITH COMPLEX ALCOHOL-AMINE SOLUTION | BEIJING BOYUAN HENGSHENG HIGH TECH CO LTD (CN) | 2021-06-30 | — | — | EP | claimed |
| EP-0758843-A4 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECH INC (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1998001136-A9 | FORMULATIONS OF VESICANT DRUGS AND METHODS OF USE THEREOF | — | 1998-04-23 | — | — | WO | claimed |
| WO-1998001136-A1 | FORMULATIONS OF VESICANT DRUGS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 1998-01-15 | — | — | WO | claimed |
| US-5629020-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-05-13 | — | — | US | claimed |
| EP-0758843-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | Emisphere Technologies, Inc. (US) | 1997-02-26 | — | — | EP | claimed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1996009813-A9 | DIKETOPIPERAZINE-BASED DELIVERY SYSTEMS | — | 1996-09-26 | — | — | WO | claimed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1995028838-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | claimed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238317-A1 | METHODS FOR REDUCING INTRAOCULAR PRESSURE | CIT, ROCK1, RHOA | SMN1; SMN2 4857/4885HDAC3 3077/4885MAPK1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.